Lisocabtagene maraleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma after 1 systemic treatment [ID3869]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Venetoclax with ibrutinib for treating relapsed mantle cell lymphoma [ID3879]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Inolimomab (Leukotac) for acute Graft versus host disease (aGvHD) after Allo-HSCT [ID3923]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Ixazomib citrate for maintenance treatment of untreated multiple myeloma after autologous stem cell transplant [ID1517]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Magrolimab with azacitidine for untreated myelodysplastic syndromes [ID3978]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Sabatolimab with azacitidine for untreated high-risk myelodysplastic syndromes [ID3996]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Isatuximab in combination for newly diagnosed multiple myeloma [ID3981]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Liposomal cytarabine–daunorubicin for treating relapsed or refractory acute myeloid leukaemia in people aged 1 to 21 years [ID4017]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Talquetamab for treating relapsed or refractory multiple myeloma after 3 therapies [ID 5082]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Navitoclax with ruxolitinib for treating myelofibrosis when stem cell transplant is unsuitable [ID5096]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Zamtocabtagene autoleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more therapies TS ID 10765Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
REGN5458 for treating relapsed or refractory multiple myeloma TS ID 10443Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Idecabtagene vicleucel for treating relapsed or refractory multiple myeloma after 2 to 4 therapies TS ID 10330Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Acalabrutinib with venetoclax and obinutuzumab for untreated chronic lymphocytic leukaemia [ID6156]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Acalabrutinib with bendamustine and rituximab for untreated mantle cell lymphoma [ID6155]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Teclistamab with daratumumab for treating relapsed or refractory multiple myeloma after 1 or more therapies [ID6201]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Daratumumab for treating high-risk smouldering multiple myeloma [ID6214]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Acalabrutinib with venetoclax for untreated chronic lymphocytic leukaemia or small lymphocytic lymphoma TS ID 11823Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Daratumumab in combination for untreated multiple myeloma when high-dose chemotherapy and autologous stem cell transplant are suitable ID6249Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Zamtocabtagene autoleucel for treating relapsed or refractory diffuse large B-cell lymphoma when high-dose chemotherapy and autologous stem cell transplant are unsuitable TS ID 10477Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Epcoritamab for treating relapsed or refractory follicular lymphoma after 2 or more treatments [ID6338]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Tazemetostat for treating relapsed or refractory follicular lymphoma after 2 or more treatments [ID6349]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Human acellular vessel (Humacyl; HAV) For use as an arterial venous access for patients with end stage renal disease (ESRD) requiring haemodialysis [ID3747]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Isatuximab in combination as induction therapy for untreated multiple myeloma when an autologous stem cell transplant is suitable TS ID 11949Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Acalabrutinib for treating relapsed or refractory mantle cell lymphoma [ID6389]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Favezelimab–pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after anti-PD-L1 treatment TS ID 11963Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Tafasitamab with lenalidomide and rituximab for treating relapsed or refractory follicular or marginal zone lymphoma after 1 or more anti-CD20 treatments ID6413Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Ruxolitinib for treating acute graft-versus-host disease after allogeneic stem cell transplant in people 28 days to 17 years [ID6410]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Obecabtagene autoleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia ID6347Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Brentuximab vedotin with etoposide, cyclophosphamide, doxorubicin, dacarbazine and dexamethasone for untreated advanced classical Hodgkin lymphoma TS ID 11987Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Blinatumomab with chemotherapy for consolidation treatment of Philadelphia-chromosome-negative CD19-positive B-precursor acute lymphoblastic leukaemia with no measurable residual disease TS ID 11991Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Zanubrutinib with obinutuzumab for treating relapsed or refractory B-cell follicular lymphoma after 2 or more treatments TSID 11915Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC